| abstract |
A modified release dosage product ( 5 ) comprises a plurality of minicapsules or minispheres ( 1, 2 ) containing nimodipine, and a plurality of minicapsules or minispheres ( 3 ), ( 4 ) containing tacrolimus. There are uncoated minicapsules or minispheres ( 1 ) encapsulating micronized nimodipine for immediate release and a controlled release polymer coated minicapsule or minisphere ( 2 ) encapsulating micronized nimodipine for delayed, sustained, controlled or targeted release. There are uncoated seamless minicapsules ( 3 ), the core of which comprises tacrolimus lipid-based formulation for immediate release and a controlled release polymer coated seamless minicapsule ( 4 ), the core of which comprises tacrolimus lipid-based formulation for delayed, sustained, controlled release or targeted release. The final dosage form may be a hard gelatin capsule ( 5 ). |